Background:To evaluate whether intracameral dexamethasone – moxifloxacin can safely and effectively reduce the postoperative inflammation, guard against endophthalmitis and improve surgical outcomes after cataract surgery.Methods:Prospective simple randomized comparative control study included 200 eyes of 200 Patients underwent uncomplicated phacoemulsification (PE). One hundered eyes were injected intracamerally with 0.1 ml moxifloxacin 0.5% and 0.4 mg dexamethasone at the end of surgery while the other 100 eyes used as a control group received intracameral placebo injection. Outcomes were measured on first postoperative day and weekly for one month by visual acuity assessment, slit lamp biomicroscopic examination, intraocular pressure (IOP), endothelial cell density (ECD) and presence of any postoperative complications. Results:200 eyes of 200 patientswere included in the study. The mean age was 56.22± 10.62y (range 34-82y). Regarding aqueous cells recorded on the first postoprativeday in group I, five eyes had 2 and 7 eyes had 1+ with no eyes of +3 or more. After 1 week follow up examination, all eyes had no anterior chamber cells. In group II, the first postoperative day showed 11 eyes with 3+, 15 eyes had 2+, 8 eyes had 1+. One week postoperatively, only 3 eyes had +1 aquous cells. All eyes of both groups had no detected anterior chamber cells at subsequent follow up visits. The effective phacoemulsification time was 3.89±0.93. The mean endothelial cell density (ECD) in group I was 2474.02 cells/mm2 ±348.21 preoperatively and in 2274.15 cells/mm2 ±330.09. In group II preoperative ECC was 2369.16 cells/mm2 ±394.13, and postoperative was 2200.96 cells/mm2 ± 351.12 one month postoperatively (P≤0.001). There was no significant effect on IOP values with no detected long term complications .Conclusions:Intracameral dexamethasone- moxifloxacin injected at the end of cataract surgery reduces the postoperative AC cells significantly and improves patient's compliance in early postoperative follow period with no significant risk of IOP elevation.